Business Description
Oncoinvent ASA
ISIN : NO0013711713
Total Employee Number:
44Description
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 52.44 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.62 | |||||
Beneish M-Score | 2.93 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -12.5 | |||||
3-Year EBITDA Growth Rate | 82.5 | |||||
3-Year EPS without NRI Growth Rate | 83 | |||||
3-Year FCF Growth Rate | 82.8 | |||||
3-Year Book Growth Rate | -81.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 58.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 98.25 | |||||
9-Day RSI | 93.01 | |||||
14-Day RSI | 88.38 | |||||
3-1 Month Momentum % | 94.47 | |||||
6-1 Month Momentum % | 90.67 | |||||
12-1 Month Momentum % | 17.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.43 | |||||
Quick Ratio | 2.43 | |||||
Cash Ratio | 2.24 | |||||
Days Sales Outstanding | 39.01 | |||||
Days Payable | 469.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -554.1 | |||||
Shareholder Yield % | -20.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.17 | |||||
Operating Margin % | -787.71 | |||||
Net Margin % | -877.36 | |||||
EBITDA Margin % | -743.63 | |||||
FCF Margin % | -686.55 | |||||
OCF Margin % | -686.37 | |||||
ROE % | -174.67 | |||||
ROA % | -122.27 | |||||
ROIC % | -387.19 | |||||
3-Year ROIIC % | 2794.31 | |||||
ROC (Joel Greenblatt) % | -1715.86 | |||||
ROCE % | -156.46 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 14.41 | |||||
PB Ratio | 7.47 | |||||
Price-to-Tangible-Book | 7.47 | |||||
EV-to-EBIT | -3.24 | |||||
EV-to-EBITDA | -3.43 | |||||
EV-to-Revenue | 25.51 | |||||
EV-to-Forward-Revenue | 1129.65 | |||||
EV-to-FCF | -3.72 | |||||
Price-to-GF-Value | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 8.85 | |||||
| Price-to-Net-Cash | 10.18 | |||||
Earnings Yield (Greenblatt) % | -30.86 | |||||
FCF Yield % | -22.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncoinvent ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 19.508 | ||
| EPS (TTM) (kr) | -83.2 | ||
| Beta | -0.1321 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.17 | ||
| Volatility % | 82.6 | ||
| 14-Day RSI | 88.38 | ||
| 14-Day ATR (kr) | 4.230127 | ||
| 20-Day SMA (kr) | 92.53787 | ||
| 12-1 Month Momentum % | 17.49 | ||
| 52-Week Range (kr) | 40.2 - 135 | ||
| Shares Outstanding (Mil) | 4.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncoinvent ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncoinvent ASA Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 09:30 | In 166 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 165 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-27 10:00 | 85.40 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-27 07:00 | 85.40 (+0.00%) | ||
| General meeting for 2025 | 2026-05-20 10:00 | 46.10 (+0.00%) | ||
| Guidance call for 2026 | 2026-04-29 08:00 | 48.00 (+0.00%) | ||
| Annual report for 2025 | 2026-04-22 | 48.90 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 09:30 | 46.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 46.00 (+0.00%) | ||
| 0.01:1 Stock Split | 2026-01-19 | 44.00 (+0.00%) |
Show
Entries
Oncoinvent ASA Frequently Asked Questions
What is Oncoinvent ASA(LTS:0RU5)'s stock price today?
The current price of LTS:0RU5 is kr134.00. The 52 week high of LTS:0RU5 is kr135.00 and 52 week low is kr40.20.
When is next earnings date of Oncoinvent ASA(LTS:0RU5)?
The next earnings date of Oncoinvent ASA(LTS:0RU5) is 2027-02-26 Est..
Does Oncoinvent ASA(LTS:0RU5) pay dividends? If so, how much?
Oncoinvent ASA(LTS:0RU5) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers